Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment
Sign Up to like & getrecommendations! Published in 2021 at "Obesity Medicine"
DOI: 10.1016/j.obmed.2020.100312
Abstract: COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a pandemic since WHO made the statement on March 11, 2020. The infection is causing a high mortality in old people, especially those… read more here.
Keywords: treatment; glp agonists; friend foe; foe ace2 ... See more keywords
Discovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.4c02616
Abstract: Glucagon-like peptide-1 receptor (GLP-1R) is a well-established target for the treatment of type 2 diabetes mellitus (T2DM) and obesity. The development of orally bioavailable and long-acting small-molecule GLP-1R agonists is a pursuit in both academia… read more here.
Keywords: glp; orally bioavailable; selenium containing; bioavailable glp ... See more keywords
GLP-1 agonists: a game changer in pain treatment and addiction.
Sign Up to like & getrecommendations! Published in 2025 at "Pain management"
DOI: 10.1080/17581869.2025.2536998
Abstract: Chronic pain imposes a significant healthcare burden, with treatments often limited by side effects, opioid dependency, and preventable surgeries. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), developed for diabetes and obesity, may offer… read more here.
Keywords: addiction; pain management; pain; glp agonists ... See more keywords
Glucagon-Like Peptide-1 Agonists
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Plastic Surgery"
DOI: 10.1097/sap.0000000000004089
Abstract: Background Glucagon-like peptide-1 (GLP-1) agonists, such as exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide, effectively manage type 2 diabetes by promoting insulin release, suppressing glucagon secretion, and enhancing glucose metabolism. They also aid weight reduction and… read more here.
Keywords: glp agonists; plastic surgery; glycemic control;
GLP‐1 Agonists for Pediatric Psychopharmacology: Opportunities and Cautions
Sign Up to like & getrecommendations! Published in 2025 at "Clinical and Translational Science"
DOI: 10.1111/cts.70262
Abstract: Glucagon‐like peptide‐1 agonists (GLP‐1A) are increasingly prescribed to treat obesity and type 2 diabetes mellitus in children and adolescents. Emerging evidence suggesting neuropsychiatric effects presents an opportunity for pediatric psychopharmacology but requires careful consideration of… read more here.
Keywords: opportunities cautions; psychopharmacology opportunities; agonists pediatric; psychopharmacology ... See more keywords
GLP‐1 agonists and hair loss: a call for further investigation
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Dermatology"
DOI: 10.1111/ijd.17246
Abstract: The widespread adoption of glucagon‐like peptide‐1 (GLP‐1) agonists in treating type 2 diabetes mellitus (T2DM) and obesity has sparked investigations into their impact on hair health, an area characterized by diverse conjectures. Some propose potential… read more here.
Keywords: glp agonists; agonists hair; hair loss; loss call ... See more keywords
Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?
Sign Up to like & getrecommendations! Published in 2025 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-25-0991
Abstract: Glucagon-like peptide 1 receptor agonists hold great promise to reverse some cancer risk in people living with obesity, and emerging clinical trials support this so far. However, some preclinical work and caveats from human studies… read more here.
Keywords: cancer; obesity; weaken links; links obesity ... See more keywords
Abstract 4145342: GLP-1 Agonists are Associated with Fewer Unplanned Hospital Visits in Patients with Cardiovascular Disease and Comorbid Substance Use Disorder
Sign Up to like & getrecommendations! Published in 2024 at "Circulation"
DOI: 10.1161/circ.150.suppl_1.4145342
Abstract: Background: Improved outcomes related to the use of glucagon-like peptide 1 (GLP-1) agonists in patients with cardiovascular disease (CVD) have been well documented. Small studies have shown benefits of GLP-1 agonists in reducing substance use… read more here.
Keywords: use; glp agonists; hospital visits; cvd ... See more keywords
Asthma Exacerbations in Type 2 Diabetics with Asthma on Glucagon-like Peptide-1 Receptor Agonists.
Sign Up to like & getrecommendations! Published in 2020 at "American journal of respiratory and critical care medicine"
DOI: 10.1164/rccm.202004-0993oc
Abstract: RATIONALE Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2 diabetes mellitus and obesity. GLP-1R agonists reduce airway inflammation and hyperresponsiveness in preclinical models. OBJECTIVES To compare rates of asthma exacerbations and symptoms… read more here.
Keywords: glp agonists; like peptide; peptide receptor; glucagon like ... See more keywords
A Review of the Renoprotective Effects of Novel Antidiabetic Agents
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Pharmacy Practice"
DOI: 10.1177/0897190020902344
Abstract: The objective of this review article was to identify and examine current evidence surrounding the potential renoprotective effects of newer antidiabetic agents such as sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucose-like peptide 1 (GLP-1) agonists, and… read more here.
Keywords: review renoprotective; sglt inhibitors; renoprotective effects; inhibitors glp ... See more keywords
PSUN192 Therapeutic Benefit of GLP-1 Agonists in Patients with Type 1 Diabetes on Insulin Therapy: an Updated Systematic Review and Meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the Endocrine Society"
DOI: 10.1210/jendso/bvac150.782
Abstract: Abstract Introduction Glucagon-like Peptide 1 (GLP-1) agonists are efficacious glycemic control and weight loss agents for obese patients with or without type 2 diabetes mellitus. Use of GLP-1 agonists for patients with type 1 diabetes… read more here.
Keywords: meta analysis; glp agonists; analysis; type diabetes ... See more keywords